Latest Headlines

July 27, 2026

FDA Approves Centanafadine for ADHD

The first approved norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD demonstrated symptom improvements as early as week 1 in phase 3 trials.

Conexiant

July 27, 2026

Does Exercise Inhibit Myopia Progression in Children?

Randomized trials suggested exercise may improve visual function while modestly reducing structural markers of myopia, with benefits varying by intervention strategy.

Conexiant

July 24, 2026

FDA Approves Acetaminophen/Naproxen Sodium

The fixed-dose combination product combines acetaminophen with naproxen sodium and is labeled to provide up to 12 hours of temporary pain relief.

Conexiant

July 24, 2026

Cannabinoids Fall Short Across Most Psychiatric Disorders

"[T]he routine use of cannabinoids for the treatment of mental disorders and SUDs is rarely justified."

Conexiant

July 24, 2026

Bringing it Home: Why We Switched to In-House WGS

Annette Kim shares her experience of a real-world clinical laboratory transition to whole-genome sequencing

The Pathologist

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

July 23, 2026

New Data for Acquired Hypothalamic Obesity

Researchers found greater reductions in body mass index and participant-reported hunger scores with setmelanotide than with placebo, although adverse and serious adverse events were more frequent in the setmelanotide group; only one serious adverse event was considered treatment-related.

Conexiant

July 22, 2026

FDA Expands Pediatric Allergy Nasal Spray Use

A phase 3 randomized, double-blind, placebo-controlled trial in pediatric patients demonstrated improved nasal symptoms compared with placebo.

Conexiant

July 22, 2026

Medical Oddities: When AI Meets the Afterlife

Ghosts, germs, B cells, and brews—this week's research is anything but ordinary.

Conexiant

July 20, 2026

MMRV Use May Reveal Vaccine Access Gaps

The study identified the populations most likely to be affected by reduced access to MMRV.

Conexiant

July 17, 2026

FDA Grants Traditional Approval to Iptacopan in Primary IgAN

Novartis reported less annual eGFR decline with iptacopan than placebo over 2 years in the phase 3 APPLAUSE-IgAN trial.

Conexiant

Medical Oddities: Natural Doesn't Always Mean Safe

Latest Headlines

FDA Approves Centanafadine for ADHD

Does Exercise Inhibit Myopia Progression in Children?

FDA Approves Acetaminophen/Naproxen Sodium

Cannabinoids Fall Short Across Most Psychiatric Disorders

Bringing it Home: Why We Switched to In-House WGS

Daily News

New Data for Acquired Hypothalamic Obesity

FDA Expands Pediatric Allergy Nasal Spray Use

Medical Oddities: When AI Meets the Afterlife

MMRV Use May Reveal Vaccine Access Gaps

FDA Grants Traditional Approval to Iptacopan in Primary IgAN

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

Medical Oddities: Natural Doesn't Always Mean Safe

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dentistry

ADA News

CDE World

New Dentist News

Conexiant

AACE Endocrinology AI

Conexiant

GI & Hepatology News

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

The Medicine Maker

The Analytical Scientist

Latest Headlines

Daily News

Recommendations